Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

Advances in advanced prostate cancer from ESMO 2012; focus on abiraterone...

Dr Chris Parker , Dr Charles Ryan, Prof Karim Fizazi

Advances in advanced prostate cancer from ESMO 2012; focus on abiraterone acetate ( Dr Chris Parker , Dr Charles Ryan, Prof Karim Fizazi )

Personalised cancer medicine and research: Today’s best practice

Prof José Baselga - Massachusetts General Hospital, Boston, USA

Personalised cancer medicine and research: Today’s best practice ( Prof José Baselga - Massachusetts General Hospital, Boston, USA )

A proof-of-concept study of ODM-201 in patients with progressive castration...

Dr Christophe Massard - Institute Gustave Roussy, Paris, France

A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer ( Dr Christophe Massard - Institute Gustave Roussy, Paris, France )

Prostate cancer screening and treatment

Prof Otis Brawley - Emory University, Georgia, USA

Prostate cancer screening and treatment ( Prof Otis Brawley - Emory University, Georgia, USA )

BRCA carrier status as a prognostic factor for prostate cancer

Dr Elena Castro - The Institute of Cancer Research, Sutton, UK

BRCA carrier status as a prognostic factor for prostate cancer ( Dr Elena Castro - The Institute of Cancer Research, Sutton, UK )

Retrospective study of optimal treatment for intermediate-risk testes cancer

Dr Constantine Albany - Indiana University, Indianapolis, USA

Retrospective study of optimal treatment for intermediate-risk testes cancer ( Dr Constantine Albany - Indiana University, Indianapolis, USA )

ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana...

ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana-Farber Cancer Institute, USA )

ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate...

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from...

ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate COU-AA-302 study ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut Gustave Roussy, France )

ASCO 2012: Advances in pre-operative care in high-risk mCRCP

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD...

ASCO 2012: Advances in pre-operative care in high-risk mCRCP ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD Anderson Cancer Centre, USA )

ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first...

Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard...

ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first-line cabazitaxel ( Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, France )

ASCO 2012: Advances in metastatic castration-resistant prostate cancer with...

Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada...

ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abiraterone ( Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Cancer Institute, USA )

Intermittent hormonal therapy versus continuous therapy for advanced prostate...

Dr Maha Hussain - University of Michigan, Ann Arbor, USA

Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )

More from ecancer